Rodrigo Vazquez-Lombardi active positions
| Companies | Position | Start | End |
|---|---|---|---|
Engimmune Therapeutics AG
 Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023. | Chief Tech/Sci/R&D Officer | 2020-12-31 | - |
| Founder | 2020-12-31 | - |
Career history of Rodrigo Vazquez-Lombardi
Statistics
International
| Switzerland | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sectoral
| Technology Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Engimmune Therapeutics AG
Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023. | Technology Services |
